ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Zacks07-23

Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453124087?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071","is_english":true,"pubTime":"2024-07-23 02:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2453124087","market":"us","top_or_hot":-1,"title":"ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment","media":"Zacks","content":"<div>\n<p>Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-focus-competition-heats-weight-180900279.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nETFs in Focus as Competition Heats Up in Weight Loss Drug Segment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-23 02:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/etfs-focus-competition-heats-weight-180900279.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-focus-competition-heats-weight-180900279.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0672654240.SGD","symbol_name":"FTIF - Franklin US Opportunities A Acc SGD-H1","start_time":0,"source_url":"https://finance.yahoo.com/news/etfs-focus-competition-heats-weight-180900279.html","article_id":"2453124087","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/g.raN2f2Gj9gsgHh3Sjz.Q--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453124087","pubTimestamp":1721671740,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are now at the forefront of medical advancements in weight management.GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%.Shares of those companies slid due to rising competition. Roche recently announced encouraging Phase I trial data for its new obesity drug candidate, CT-996, acquired through Carmot Therapeutics. The once-daily pill showed a placebo-adjusted average weight loss of 6.1% in obese patients without Type 2 diabetes within four weeks. Roche's chief medical officer, Levi Garraway, emphasized the pot","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4516":"特朗普概念","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","OZEM":"Roundhill GLP-1 & Weight Loss ETF","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4585":"ETF&股票定投概念","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4534":"瑞士信贷持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4007":"制药","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","FDN":"First Trust Dow Jones Internet I","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","BK4550":"红杉资本持仓","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","NVO":"诺和诺德","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","HRTS":"Tema Cardiovascular and Metabolics ETF","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LLY":"礼来"},"translate_title":"随着减肥药领域竞争加剧，ETF成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":1,"LLY":1,"HRTS":1,"NVO":1,"OZEM":1,"FDN":0.9},"content_text":"Global obesity rates have nearly tripled since 1975 and are expected to affect over half the population by 2035, per WHO and Goldman Sachs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy, and Zepbound, are now at the forefront of medical advancements in weight management.\nGLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%.\nTwo companies — Eli Lilly LLY and Novo Nordisk NVO — have so far dominated the weight-loss drug market and their shares have surged over the past year due to soaring demand for their products. However, shares of Eli Lilly (known for Zepbound) lost 6.3% on Jul 18, and shares of Novo Nordisk (known for Wegovy) are down 4% on Jul 18, 2024. Danish biotech firm Zealand Pharma, also in the obesity treatment race, saw an 8.4% drop in its shares.\nShares of those companies slid due to rising competition. Roche recently announced encouraging Phase I trial data for its new obesity drug candidate, CT-996, acquired through Carmot Therapeutics. The once-daily pill showed a placebo-adjusted average weight loss of 6.1% in obese patients without Type 2 diabetes within four weeks. Roche's chief medical officer, Levi Garraway, emphasized the potential for CT-996 to address both weight management and glycemic control.\nMarket Impact on Competitors\nDespite Roche's promising results, CEO Teresa Graham indicated that the widespread availability of oral obesity treatments may still be several years away. The competition in the weight loss drug market is becoming cutthroat, primarily due to the appeal of non-injectable alternatives such as Roche's CT-996.\nETFs in Focus\nAgainst this backdrop, below we highlight a few pureplay weight-loss drug maker ETFs that can be tapped on this soaring trend.\nObesity & Cardiometabolic ETF (HRTS)\nThe Tema Obesity & Cardiometabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against obesity and cardiometabolic diseases. The fund charges 75 bps in net fees. The fund has about $83.2 million.\nThe fund has 43 holdings in total. Vertex Pharma (6.17%), Amgen (5.47%) and Eli Lilly (5.29%) are the top three stocks of the fund. The United States takes 78.22% of the fund, followed by Denmark (8.05%) and the United Kingdom (3.64%).\nAmplify Weight Loss Drug & Treatment ETF (THNR)\nThe newly-launched Amplify Weight Loss Drug & Treatment ETF seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund charges 59 bps in fees.\nThe 22-stock fund is heavy on Eli Lilly (15.71%) and Novo Nordisk A/S (14.98%). Drug manufacturers take about 70% of the fund, while enablers take the rest.  The United States takes 51% of the fund, followed by Denmark (18%) and Japan (10%).\nRoundhill GLP-1 & Weight Loss ETF (OZEM)\nThe 32-stock fund, which also made a recent entry, provides exposure to companies involved in the development of pharmaceutical drugs and supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and maintain body composition during weight loss. OZEM is an actively managed ETF. The fund charges 59 bps in fees.\nThis fund is heavy on Eli Lilly (20.93%) and Novo Nordisk A/S (20.70%). Pharma stocks take about 66.4% of the fund while biotechnology (30.9%) takes the next big chunk. The United States occupies 53% of the fund, followed by Denmark (26%) and Japan (6.9%).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nTema Obesity & Cardiometabolic ETF (HRTS): ETF Research Reports\nAmplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports\nRoundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453124087"}